PPARγ agonist (pioglitazone) restored IFNγ production in tumor-infiltrating iNKT cells from patients and mice, and in combination with an immunostimulant (α-galactosylceramide), enforced iNKT cell-driven anti-tumor responses for prolonged animal survival. This evidence concerns the gene IFNG and neoplasm.